GlaxoSmithKline's Trial Proves Efficacy of HIV's Prevention Cabotegravir
May 18 2020 - 2:59AM
Dow Jones News
By Sabela Ojea
GlaxoSmithKline PLC said Monday that interim analysis of the HIV
Prevention Trials Network 083 study has proved the efficacy and
safety of investigational, long-acting, injectable cabotegravir
inhibitor for HIV prevention.
The British pharmaceutical giant said that the study of
cabotegravir was 69% more effective in preventing HIV acquisition
when administered every two months in men who have sex with men and
transgender women who have sex with men "when compared to the
current standard of care, daily oral emtricitabine/tenofovir"
drugs.
The London-listed company added that the study had around 4,600
participants across America, Asia and Africa.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 18, 2020 02:44 ET (06:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024